Welcome to our dedicated page for Aravive news (Ticker: ARAV), a resource for investors and traders seeking the latest updates and insights on Aravive stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aravive's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aravive's position in the market.
Aravive, Inc. (Nasdaq: ARAV) announced the successful completion of its Phase 1b trial for AVB-500 in platinum-resistant ovarian cancer, achieving an overall response rate (ORR) of 60% in untreated patients. The firm is on track to discuss a potential pivotal trial with the FDA and initiate a Phase 1b/2 trial for AVB-500 in clear cell renal cell carcinoma in the second half of 2020. Financially, Aravive reported zero revenue for Q2 2020, a net loss of $5.0 million, and maintains a cash position of $60.1 million, sufficient to fund operations into 2022.
Aravive, Inc. (Nasdaq: ARAV) announced the successful completion of the Phase 1b trial for its AVB-500 drug candidate in platinum-resistant ovarian cancer. A recommended Phase 2 dose of 15 mg/kg has been selected. The trial included 84 subjects, indicating AVB-500 was well-tolerated, with no dose-limiting toxicities. Preliminary efficacy data show a promising overall response rate, particularly in patients achieving a minimum efficacious concentration. Aravive plans to discuss these results and the Phase 2/3 trial strategy with the FDA by year-end 2020.
Aravive, Inc. (Nasdaq: ARAV) announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective June 29, 2020. This marks a significant milestone for the clinical-stage biopharmaceutical company, which is focused on developing treatments for cancer and fibrosis. CEO Gail McIntyre stated that this inclusion is expected to enhance the company's visibility and positively impact stock liquidity. The Russell indexes are utilized by approximately $9 trillion in assets, indicating the potential for increased interest from institutional investors.
Summary not available.